ALK-Abelló A/S (ALK-B) - Stock Price & Dividends

ALK-Abelló A/S is a leading allergy solutions company that operates in Europe, North America, and internationally, dedicated to providing innovative solutions for people suffering from allergies.

The company's product portfolio is extensive, featuring a range of treatments for allergic rhinitis and allergic asthma, including GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK. These products are designed to combat various allergies, such as grass, ragweed, house dust mite, Japanese cedar, tree, and food allergies, and are available in different forms, including injections, sublingual drops, and tablets.

ALK-Abelló A/S goes beyond just treatment, offering a comprehensive consumer healthcare solution through its Digital eco-system. This platform connects and engages with allergy sufferers throughout their disease journey, providing tools, guidance, and relief. The platform also offers e-commerce solutions, making it easier for patients to access the support they need.

In addition to its treatment and consumer healthcare solutions, the company provides diagnostic allergy solutions, including skin prick tests and blood tests. In emergency situations, ALK-Abelló A/S also offers adrenaline injections for the treatment of acute life-threatening allergic reactions, including Anaphylaxis.

The company has formed a strategic collaboration with Torii Pharmaceutical Co., Ltd. to develop, market, and distribute an allergy immunotherapy tablet for the treatment of grass pollen allergy. With a rich history dating back to 1923, ALK-Abelló A/S is headquartered in Horsholm, Denmark, and continues to innovate and improve the lives of people with allergies.